GeneTether Therapeutics Inc. Share Price

Equities

GTTX

CA37187D1087

Biotechnology & Medical Research

Delayed Canadian Securities Exchange 14:30:00 16/04/2024 BST 5-day change 1st Jan Change
0.045 CAD -.--% Intraday chart for GeneTether Therapeutics Inc. -.--% +12.50%

Financials

Sales 2022 - Sales 2023 - Capitalization 1.17M 1.6M 93.37M
Net income 2022 -1M -1.37M -79.87M Net income 2023 - 0 0 EV / Sales 2022 -
Net cash position 2022 1.8M 2.46M 143M Net cash position 2023 1.36M 1.87M 109M EV / Sales 2023 -
P/E ratio 2022
-1.84 x
P/E ratio 2023
-2.03 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 22.49%
More Fundamentals * Assessed data
Dynamic Chart
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2024. CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2023. CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-MAR-2023. CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
5,174,558 Common Shares of GeneTether Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 30-SEP-2022. CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
GeneTether Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
GeneTether Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
GeneTether Therapeutics Inc. has completed an IPO. CI
GeneTether Therapeutics Inc. announced that it has received CAD 4.5 million in funding CI
More news
3 months-10.00%
6 months+28.57%
Current year+12.50%
More quotes
Current year
0.03
Extreme 0.03
0.05
1 year
0.02
Extreme 0.015
0.05
3 years
0.01
Extreme 0.005
0.68
5 years
0.01
Extreme 0.005
0.68
10 years
0.01
Extreme 0.005
0.68
More quotes
Managers TitleAgeSince
Founder 70 11/02/18
Chief Executive Officer 57 30/09/21
Director of Finance/CFO 37 30/09/21
Members of the board TitleAgeSince
Founder 58 11/02/18
Chief Executive Officer 57 30/09/21
Director/Board Member 64 30/09/21
More insiders
Date Price Change Volume

Delayed Quote Canadian Securities Exchange, April 16, 2024 at 02:30 pm

More quotes
GeneTether Therapeutics Inc. is a Canada-based genetic medicines company focused on creating gene editing therapies based on its proprietary GeneTether platform. The Company's platform technology uses a proprietary method to tether donor deoxyribonucleic acid (DNA) templates to the genome editing complex, making the template readily available for use during the genome editing repair stage. By positioning a donor DNA template directly at the site of a double strand break, the Company's GeneTether platform drives the DNA repair process towards homology-directed repair (HDR), a cellular repair mechanism that incorporates the genetic information of a DNA template. It is building a discovery pipeline focused on the treatment of rare, monogenic diseases of the kidney and the skin. The Company's GeneTether platform may also allow for high fidelity engineering of cells to permanently deliver the therapeutic proteins necessary to treat certain genetic diseases.
More about the company